Róbert Wessman

Petar Vazharov is the Chief Executive Officer of Lotus and responsible for leading Lotus's management and business expansion, and strategic execution.

Mr. Vazharov has over 30 years of Pharma industry experience. He spent nine years with the generic pharmaceutical company Actavis Group in various roles and has demonstrated his ability to lead the CEE business. In 2020, he started to lead Lotus to expand its global business and formulate a complete market strategy to achieve long-term and stable growth goals.

After the deal that Aztiq and Innobic became the main shareholders of Lotus, Petar said: "We are so excited to kick off another new chapter of Lotus's journey with the combined efforts from industry veteran and regional leader. Lotus has achieved several major milestones and is now the largest generic company in Taiwan. Again, this transaction is a testimonial for all the achievements Lotus has made during the past few years and great recognition by these two long-term partners for Lotus. Innobic and Aztiq will support Lotus's existing strategy and fuel the growth by bringing new opportunities, experience, and resources."

Petar graduated with a medical doctor's degree from Sofia University of Medicine in 1999 and has an MBA degree from the University of Sofia "Kliment Ohridski" in October 2007.

Petar Vazharov

Thor Kristjansson is a Partner in Aztiq, owner of multiple pharmaceutical assets. He has over 30 years of pharmaceutical and private equity experience.

Thor was an EVP of Corporate Finance and M&A for Alvogen´s global operation for over 10 years, prior to that he served as a Deputy CEO of Actavis, a global pharmaceutical company that was later acquired by Teva. His key focus throughout his career has been on corporate development and M&A. 

Thor has been a member of Lotus Board of Directors since 2014. He has held multiple BOD positions for various public and private companies in various industries, including pharmaceuticals, financial services/banking, shipping and seafood. He served as a BOD member and as a Vice Chairman of West Ham United football club from 2005 to 2007.

Thor Kristjánsson

Arni Hardarson is a director on Alvogen’s Board of Directors and serves as Deputy to the CEO.

Prior to joining Alvogen in 2009, Hardarson worked for Deloitte in Iceland where he headed the Tax and Legal departments and soon went on to become a partner and member of the Executive Management Committee for Deloitte in 2001.

In 2005 Hardarson joined Actavis as Vice President of Tax and Structure. During his tenure there, he worked closely with Robert Wessman and contributed to Actavis’ transformation from a regional manufacturer into a global pharmaceutical company, by engineering numerous company acquisitions that ultimately led to Actavis’ presence in over 40 countries around the world.

Arni Hardarson holds a Master’s degree in Law from the University of Iceland and is a member of the Icelandic Bar Association.

Arni Hardarson

Ms. Krisana Winitthumkul is Director at Innobic (Asia) and, working closely with Thai Health Authorities and associations to drive the change in regulatory requirements, actively participate in ASEAN Harmonization for Pharmaceutical Registration. She also involves in monitoring the external environment, which impacts the healthcare industry, and strengthens collaboration and regulatory reform activities in the Thai Health System.

Ms. Krisana has more than 30 years of experience in the pharmaceutical industry. She was the Regulatory Affairs and Quality Assurance Lead of Roche Thailand Ltd and worked at other big pharma in charge of regulatory affairs. In addition, she has served as the Vice President of the Regulatory Affairs Pharmaceutical Association of Thailand (RAPAT) for a long time, accumulating rich experience in regulations.

Ms. Krisana obtained her Bachelor's degree in Pharmacy from Chiang Mai University, Thailand, and her Certificate from Sasin Executive Education Center.

KrisanaWinitthumkul

Ms. Phannalin Mahawongtikul joined Lotus’ Board of Directors on June 30th, 2022. She is the Chief Financial Officer of PTT Public Company Ltd. and is also a member of the Risk Management Committee at Thai Oil Public Company Ltd.

Ms. Phannalin obtained both her MBA and Bachelor of Accounting from Thammasat University.

Phannalin Mahawongtikul

Ms. Oranee Tangphao-Daniels joined Lotus’ Board of Directors on June 30th, 2022. Ms. Oranee has more than 30 years in the pharma industry. She worked for Eli Lilly as a Clinical Pharmacologist/Clinical Research Physician and Amgen as Director to Executive Director. She is now the Chief Medical Officer at Antiva Biosciences, a novel topical therapies development company focusing on pre-cancerous lesions caused by HPV.

Ms. Oranee holds a Master’s degree in Cardiovascular Pharmacology from Mc Master University and graduated from Chulalongkorn University with a Bachelor of Medicine (Internal Medicine). She was a Post-Dec then Research Associate at Standford University from 1994 to 2000.

Oranee Tangphao-Daniels, MD

Mr. Yves Hermes joined Lotus’ Board of Directors on June 30th, 2022. He worked at SGS Asia Pacific as a Financial Analyst and became Managing Director for SGS Korea and Japan from 2000-2005. Mr. Hermes was then heading Zuellig Pharma Taiwan, Thailand, and serving as Area Director for Southeast Asia at Zuellig Pharma International Services before he founded his own company – Yves Hermes Healthcare Consultancy, in 2021.

Mr. Hermes graduated from the University of Geneva, Switzerland, and obtained a Bachelor of Economics and Finance.

Yves Hermes

Mr. Palsson joined Lotus’s Board of Directors on April 23rd, 2015. He currently serves as independent non-executive Board member and Business Consultant in various different sectors, including financial, pharmaceuticals, telecommunications and non-profits organizations across the world. Mr. Palsson is also the Chairman of Lotus’s Audit Committee.

Mr. Palsson was EVP and CFO of a leading medical device company, listed on NASDAQ OMX Copenhagen, from 2001 to 2013. He gained comprehensive experience in leading Accounting, Planning, Investor Relations, Financing, Corporate M&A, Human Resources and Business Information Services there. Prior to that, Mr. Palsson was a partner and a Board member at Deloitte & Touche in Iceland where he practiced as a State Authorized Public Accountant. 

Hjorleifur Palsson

Mr. Benjamin Ku is Attorney at Law in Cheng & Ku Law Firm and serves as an independent director of Lotus. He has 15 years of experience as a professional lawyer in various law firms in Taiwan and as in-house counsel for Taiwan corporations.

Mr. Ku passed his bar exam in 1999 and patent agent certification in Taiwan in 2001. He is a member of Taipei Bar, Keelung Bar, Taoyuan Bar, and Taichung Bar Associations in Taiwan.

Mr. Ku holds a Master of Laws in Intellectual Property Rights from Franklin Pierce Law School in the United States, is a researcher in the Intellectual Property Rights Licensing Department of the Massachusetts Institute of Technology, and a graduate from the Department of Law of National Chengchi University.

Benjamin Ku

Han-Fei Lin joined Lotus’s Board of Directors on June 27th, 2016. 

Mr. Lin is currently the Chairman of Easywell Biomedicals, Inc. He has been a Partner and the Chief Strategy Officer with the CID Group since 2004. His earlier experience included serving as CFO for one of the largest fabless IC-design companies, MStar. During his tenure with MStar, he led MStar IPO (ranked as one of the largest IPOs in Taiwan Stock Exchange history). He later completed its merger with Mediatek to create the leading semiconductor company in the Greater China region. 

Han-Fei started his career on Wall Street across various functions, including Corporate Strategy Planning for Citigroup’s Chairman office and Vice President, Mergers and Acquisitions for Citigroup/Salomon Smith Barney. In addition, Han-Fei had funded early-stage biotech ventures and served as CEO of Asia Bioinnovations. Before this, Han-Fei served as Director of Investments for Foxconn’s US ventures. 

Han-Fei Lin

Lotus’s Board of Directors consists of eleven distinguished members with an exceptional knowledge and experience in the related fields, with a balanced diversity of professions, experiences, as well as gender. Three out of eleven directors are independent directors and perform their duties in accordance with the Company’s Articles of Incorporation and relevant bylaws to protect the interests of all shareholders.

The Board of Directors supervises the Company’s operation and compliance with relevant laws and regulations as well as provides guidance to the Company’s management team to maximize shareholders' value in the long run.  The Board of Directors is also responsible for evaluating the management team’s performance and ensuring the team running the business operations in a disciplined and prudent way.